ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BIOSU BioPlus Acquisition Corporation

10.80
0.00 (0.00%)
10 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
BioPlus Acquisition Corporation NASDAQ:BIOSU NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 10.80 10.31 11.85 0 01:00:00

Form RW - Registration Withdrawal Request

04/10/2023 12:39pm

Edgar (US Regulatory)


BioPlus Acquisition Corp.

260 Madison Avenue

Suite 800

New York, New York 10026

October 4, 2023

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, D.C. 20549

 

Re:

BioPlus Acquisition Corp.

Registration Statement on Form S-4

Filed May 15, 2023

File No. 333-271915

Ladies and Gentleman:

Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), BioPlus Acquisition Corp. (“we,” “us,” “our,” or the “Company”) hereby submits this letter to notify the Securities and Exchange Commission (the “Commission”) of our withdrawal of our Registration Statement on Form S-4 (File No. 333-271915) initially filed with the Commission on May 15, 2023, together with all exhibits and amendments thereto (the “Registration Statement”), because the Company has elected not to proceed with the business combination contemplated by the Registration Statement at this time. The Registration Statement was not declared effective and no securities have been issued or sold under the Registration Statement.

The Company acknowledges that no refund will be made for fees paid to the Commission in connection with the filing of the Registration Statement. However, the Company requests that all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use should the Company proceed with the filing of a subsequent registration statement meeting the requirements of Rule 457(p) promulgated under the Securities Act.

Thank you for your assistance with this matter. If you have any questions or comments concerning this request, please contact our legal counsel, Peter Byrne of Cooley LLP, at pbyrne@cooley.com.

 

Sincerely,

/s/ Ross Haghighat

Ross Haghighat
Chief Executive Officer, Chief Financial
Officer and Director

 

cc:

Peter Byrne, Cooley LLP


1 Year BioPlus Acquisition Chart

1 Year BioPlus Acquisition Chart

1 Month BioPlus Acquisition Chart

1 Month BioPlus Acquisition Chart

Your Recent History

Delayed Upgrade Clock